<DOC>
	<DOCNO>NCT02155998</DOCNO>
	<brief_summary>This multicentre , non-interventional , prospective study carry representative medical institution order get information administration postoperative post-radiation adjuvant androgen deprivation therapy ( include `` go '' / `` go '' decision , regimen , dosage duration ) use locally advanced prostate cancer patient high high risk recurrence Russia .</brief_summary>
	<brief_title>Non-Interventional Study PREVENT</brief_title>
	<detailed_description>This multicentre , non-interventional , prospective study carry representative medical institution order get information administration postoperative post-radiation adjuvant androgen deprivation therapy ( include `` go '' / `` go '' decision , regimen , dosage duration ) use locally advanced prostate cancer patient high high risk recurrence Russia . No additional procedure besides already use routine clinical practice apply patient . Treatment assignment do accord current practice . It plan enrol 200 subject 30 site Russian Federation . The average number patient per site plan 6 - 10 ; restriction minimum maximum number subject per site study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . The voluntarily give informed consent , confirm Informed Consent Form , properly sign subject investigator . 2 . Locally advanced stage PCa ( stage T3T4 , NxN0 , M0 : prostate adenocarcinoma extracapsular invasion ( T3a ) invasion seminal vesicle ( T3b ) , invasion adjacent structure ( T4 ) without lymphatic invasion ( N0 ) metastasis ( M0 ) ) 3 . Prostatectomy radiotherapy complete within 3 month prior study enrolment 4 . High ( T3a Gleason score = 810 PCA &gt; 20 ng/ml ) high ( T3bT4 ) risk recurrence 5 . Histologically confirm diagnosis prostate adenocarcinoma 1 . Patients participate clinical trial 2 . Any medical condition opinion investigator may interfere patient 's participation study , e.g . severe nonmalignant concomitant disease affect life expectancy 3 . Evidence metastatic disease image study</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>prostate adenocarcinoma , locally advanced prostate cancer high high risk recurrence , adjuvant endocrine treatment , prostate specific antigen</keyword>
</DOC>